KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Cash from Discontinued Operations (2021 - 2022)

Zimmer Biomet Holdings' quarterly Cash from Discontinued Operations came in at 75300000.0 in Q4 2022, down 367.97% year-on-year from 28100000.0 in Q4 2021, and down 200.0% quarter-over-quarter from 75300000.0 in Q3 2022.

Zimmer Biomet Holdings has reported Cash from Discontinued Operations for 2 years, with the latest figure at 75300000.0 in Q4 2022.

  • For the quarter ending Q4 2022, Cash from Discontinued Operations fell 367.97% year-over-year to 75300000.0; the trailing twelve-month figure through Sep 2023 stood at 75300000.0 (down 73.5% YoY), and the FY2022 full-year result was 146800000.0, down 254.69% from the prior year.
  • Cash from Discontinued Operations for Q4 2022 stood at 75300000.0, down from 75300000.0 in the prior quarter.
  • The five-year high for Cash from Discontinued Operations was 75300000.0 in Q3 2022, with the low at 153800000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -75.30 Mn
Dec 31, 2022 -75.30 Mn
Sep 30, 2022 75.30 Mn
Sep 30, 2022 75.30 Mn
Jun 30, 2022 7.00 Mn
Jun 30, 2022 7.00 Mn
Mar 31, 2022 -153.80 Mn
Mar 31, 2022 -153.80 Mn
Dec 31, 2021 28.10 Mn
Dec 31, 2021 28.10 Mn
Sep 30, 2021 8.90 Mn
Sep 30, 2021 8.90 Mn
Jun 30, 2021 34.90 Mn
Jun 30, 2021 34.90 Mn
Mar 31, 2021 23.00 Mn
Mar 31, 2021 23.00 Mn